Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H26ClFO4 |
Molecular Weight | 408.891 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)CC(=O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=XXIFVOHLGBURIG-OZCCCYNHSA-N
InChI=1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
DescriptionSources: https://www.medicines.org.uk/emc/medicine/2607Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/12775314 and http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con239418.pdf
Sources: https://www.medicines.org.uk/emc/medicine/2607
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/12775314 and http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con239418.pdf
Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis. It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline. Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal.
Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Clobetasone butyrate relieves the symptoms of a flare-up by reducing inflammation, itching and redness. It is not a cure for the condition, but it will help to relieve the symptoms. Although less potent topical steriods are often preferred for use in children, a short course of clobetasone butyrate may be prescribed for a child with severe eczema on the arms or legs. Short courses of clobetasone butyrate may also be prescribed for the treatment of psoriasis for areas such as the face, or the inside of elbows and behind the knees. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.
Originator
Sources: http://www.nps.org.au/medicines/skin/corticosteroids-for-the-skin-topical/clobetasone-butyrate/eumovate-cream
Curator's Comment: https://en.wikipedia.org/wiki/Clobetasone
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.ncbi.nlm.nih.gov/pubmed/25965047 |
0.19 nM [EC50] | ||
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18579783 |
6080.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | EUMOVATE CREAM Approved UseEumovate Cream is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
These include the following:
- Atopic dermatitis
- Irritant or allergic contact dermatitis
- Seborrhoeic dermatitis
- Photodermatitis
- Otitis externa
- Prurigo nodularis
- Insect bite reactions Launch Date1976 |
|||
Palliative | EUMOVATE CREAM Approved UseEUMOVATE is used to treat eczema and dermatitis Launch Date1976 |
|||
Palliative | EUMOVATE CREAM Approved UseEUMOVATE is suitable for treating atopic eczema, photodermatitis, otitis externa,
primary irritant and allergic dermatitis, prurigo nodularis, seborrhoeic dermatitis, and
other steroid responsive skin conditions which do not require the use of a more active
topical corticosteroid in children and adults. Launch Date1976 |
|||
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/uk/pdf/leaflet/720431.pdf
Eumovate (clobetasone butyrate 0.05%) should be applied thinly and evenly to the affected area(s) of skin up to 2 times a day
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/81679
Clobetasone butyrate depressed proliferation of cell strains derived from normal human foreskin at 10 ug/ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01CA11
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
WHO-VATC |
QD07AB01
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
WHO-ATC |
S01CA11
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
WHO-VATC |
QS01BA09
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
WHO-ATC |
S01BA09
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
WHO-ATC |
D07AB01
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CLOBETASONE
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
258-953-5
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
SUB06679MIG
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
108074
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL2308885
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
C77408
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
3155
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
71387
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
DTXSID601023875
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
54063-32-0
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
m3629
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084302
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
DB13158
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY | |||
|
LT69WY1J6D
Created by
admin on Fri Dec 15 16:04:02 GMT 2023 , Edited by admin on Fri Dec 15 16:04:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY